中东呼吸综合征冠状病毒
医学
抗病毒药物
2019-20冠状病毒爆发
肺炎
非典型肺炎
倍他科诺病毒
抗病毒治疗
冠状病毒
2019年冠状病毒病(COVID-19)
药品
药物治疗
严重急性呼吸综合征冠状病毒2型(SARS-CoV-2)
病毒性肺炎
重症监护医学
病毒学
免疫学
内科学
疾病
传染病(医学专业)
病毒
药理学
爆发
慢性肝炎
作者
Naiwei Zhu,Ping Zhao,Zhongtian Qi
出处
期刊:Chinese journal of microbiology and immunology
日期:2020-01-31
卷期号:40 (1): 7-10
标识
DOI:10.3760/cma.j.issn.0254-5101.2020.01.002
摘要
2019 novel coronavirus (2019-nCoV) is a new member of coronavirus family that can cause serious respiratory diseases after the emergence of severe acute respiratory syndrome-coronavirus (SARS-CoV) and middle east respiratory syndrome-coronavirus (MERS-CoV). At present, there is no specific antiviral drug targeting 2019-nCoV. In facing of the increasingly serious epidemic of 2019 novel coronavirus pneumonia and the urgent needs in drug treatment strategies, this paper reviewed the current research situation and progress in antiviral treatment for the newly identified disease.
Key words:
2019 novel coronavirus; Treatment; Drugs
科研通智能强力驱动
Strongly Powered by AbleSci AI